Ian E. Krop

Ian E. Krop, MD, PhD is Associate Director for Clinical Research at Yale Cancer Center and Professor of Medicine at Yale School of Medicine. He is a world-leading expert in the development of antibody-drug conjugates (ADCs) for HER2-positive breast cancer, with a career spanning the translational development of multiple generations of HER2-directed ADCs. Dr. Krop was the lead investigator on pivotal early-phase trials of ado-trastuzumab emtansine (T-DM1), including the TDM4258g phase II study that defined the T-DM1 dose, schedule, and response profile that went forward into the successful EMILIA and KATHERINE pivotal trials. He subsequently led DESTINY-Breast01, the phase II study of trastuzumab deruxtecan (T-DXd) that demonstrated extraordinary activity (ORR ~60%) in heavily pretreated HER2+ metastatic breast cancer patients—results that led to FDA Breakthrough Therapy Designation and accelerated approval in 2019. Dr. Krop also led early studies of HER2-targeted ADC therapy in patients with HER2+ breast cancer brain metastases, a clinically challenging and underserved population. Prior to Yale, he was at Dana-Farber Cancer Institute where he built one of the premier HER2-targeted ADC development programs. He has authored more than 200 peer-reviewed publications and serves as a standing member of the FDA Oncologic Drugs Advisory Committee.